Randomized controlled trials (RCTs) demonstrate sodium-glucose cotransporter-2 inhibitors (SGLT-2Is) reduce hospitalizations for heart failure (HF) and mortality in general older populations with type 2 diabetes (Zinman et al., 2015; Perkovic et al., 2018; Filion et al., 2020). This evidence concerns the gene SLC5A2 and hydrops fetalis.